Turning Point Therapeutics Announces Management Transition

    NEXT STORY
    AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco
    PREV STORY
    T2 Biosystems Appoints Industry Veteran John Sperzel as Chief Executive Officer
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Data Monitoring Committee Completes Mid-Study Review of Celsion’s Phase III ThermoDox® OPTIMA Study in Primary Liver Cancer

    OPTIMA Study at Over 60% Patient Enrollment, DMC Provides Unanimous Recommendation to Continue Celsion ...

    author_avatar
    NASDAQ Market News

    Dr Richard Buchta Appointed as Director of Beroni Group

    author_avatar
    NASDAQ Market News

    MacroGenics Announces Participation in Three Investor Conferences

    ROCKVILLE, MD, Oct. 22, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage ...

    author_avatar
    NASDAQ Market News